Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management

Robert D. McBane, M.D.
Division of Cardiology
Mayo Clinic Rochester
Financial Disclosure Information

Dual Antiplatelet Rx Plus Systemic Anticoagulation: Bleeding Risk and Management

Robert McBane, MD

None
76 year old male

• On routine examination, he is noted to have an irregular rhythm. ECG confirms new onset atrial fibrillation. His rate is adequately controlled.

• Coronary Disease
  – Recent DES (n=2) to LAD

• PMHx:
  – Diabetes mellitus,
  – Hyperlipidemia,
  – Carotid disease (2 prior TIAs; s/p endarterectomy),
  – “Smoldering” Waldenstrom's macroglobulinemia.
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOAT</td>
<td>triple oral antithrombotic therapy</td>
</tr>
<tr>
<td>DAPT</td>
<td>dual antiplatelet therapy</td>
</tr>
<tr>
<td>OAC</td>
<td>oral anticoagulant therapy</td>
</tr>
</tbody>
</table>
Question

What antithrombotic cocktail should be used for this patient?

1. Aspirin
2. Clopidogrel (or other P2Y12 antagonist)
3. DAPT
4. OAC
5. TOAT
Question

If you offer him TOAT, what will you quote his anxious daughter regarding annual risk of major bleeding?

1. 3%
2. 6%
3. 9%
4. 15%
5. 25%
Learning Objectives

To Understand

• The magnitude of the problem
• The relative magnitude of the bleeding risk
• The comparable risk if novel anticoagulants are employed
• The utility of online tools in the bleeding risk prediction
• Recommendations for management
Resources


Magnitude of the Problem
(Combining OAC with DAPT)

U.S. disease prevalence

• **Atrial fibrillation:** 4.4 million
  30% have known CAD

• **Coronary disease:** 16 million
  >1 million coronary interventions/year
  70% include use of DES
  1 in 10 subjects with acute MI have Afib

• **250,000 patients/year with TOAT indication**

*Circulation* 2012;125:E2-220
*JACC* 2012;60:2017-31
What is the risk of major bleeding for patients taking TOAT relative to other antithrombotic combinations?
Risk of Bleeding with Single, Dual, or Triple Therapy in Patients with Atrial Fibrillation

- Nationwide Danish registry
- 118,606 patients with AF
  - Warfarin (n = 50,919)
  - Aspirin (n = 47,541)
  - Clopidogrel (n = 3,717)
  - ASA/Clop (n = 2,859)
  - Warfarin + aspirin (n = 18,345)
  - Warfarin + aspirin + clopidogrel (n = 1,261)
- 1° end point: *nonfatal bleeding requiring hospitalization* or *fatal bleeding*.

Arch Intern Med. 2010;170:1433-1441
## Risk of Bleeding with Single, Dual, or Triple Therapy in Patients with Atrial Fibrillation

<table>
<thead>
<tr>
<th>Bleeding rates*</th>
<th>Non fatal</th>
<th>Fatal</th>
<th>Both</th>
</tr>
</thead>
<tbody>
<tr>
<td>Warf</td>
<td>3.6</td>
<td>0.2</td>
<td>3.9</td>
</tr>
<tr>
<td>ASA</td>
<td>3.3</td>
<td>0.4</td>
<td>3.7</td>
</tr>
<tr>
<td>Clop</td>
<td>4.8</td>
<td>0.8</td>
<td>5.6</td>
</tr>
<tr>
<td>ASA/Clop</td>
<td>7.0</td>
<td>0.6</td>
<td>7.4</td>
</tr>
<tr>
<td>Warf/ASA</td>
<td>6.4</td>
<td>0.4</td>
<td>6.8</td>
</tr>
<tr>
<td>Warf/clop</td>
<td>13.3</td>
<td>0.6</td>
<td>13.9</td>
</tr>
<tr>
<td>Warf/ASA/clop</td>
<td>15.4</td>
<td>0.2</td>
<td>15.7</td>
</tr>
</tbody>
</table>

*Incidence rate: % per patient-year

Arch Intern Med. 2010;170:1433-1441
## Registry Studies

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>DAPT</th>
<th>OAC</th>
<th>TOAT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buresly</td>
<td>21,443</td>
<td>6.8%</td>
<td>5.9%</td>
<td>8.5%</td>
</tr>
<tr>
<td>Sorensen</td>
<td>40,812</td>
<td>3.7%</td>
<td>4.3%</td>
<td>12.0%</td>
</tr>
<tr>
<td>Lamberts</td>
<td>11,480</td>
<td>7.0%</td>
<td>7.0%</td>
<td>14.2%</td>
</tr>
<tr>
<td>Hansen</td>
<td>118,606</td>
<td>7.4%</td>
<td>3.9%</td>
<td>15.7%</td>
</tr>
</tbody>
</table>

TOAT increases risk
- 2 fold relative to DAPT
- 3 fold relative to OAC or antiplatelet mono-therapy

Clin Cardiol 2013; July
Is TOAT more effective than OAC plus clopidogrel for thromboembolic event reduction?
Clopidogrel ± aspirin in patients taking OAC undergoing PCI

WOEST Trial

Patients: Patients undergoing PCI with an OAC indication*
Exclusions: ICH hx, shock, PUD, tpenia, major bleed hx

573 patients

TOAT

Warfarin plus clopidogrel

Primary endpoint: any bleeding episode within 1st year
Secondary endpoint: death, MI, stroke, TVR, stent thrombosis

*Lafib 69%, MHV 11%, Other 20%

Lancet 2013; 381: 1107–15
Cumulative Incidence: Any Bleeding

HR 0.36, 95% CI 0.26 – 0.50  P<0.0001
Major bleeding (TIMI, GUSTO, BARC): NS

Lancet 2013; 381: 1107–15
Cumulative Incidence: MACE

HR 0.60, 95% CI 0.38 – 0.94  P<0.025

Major bleeding (TIMI, GUSTO, BARC): NS

Lancet 2013; 381: 1107–15
TOAT vs. OAC plus clopidogrel

• These results suggest that OAC/clopidogrel carries lower bleeding risk without increased thromboembolism.
• Further RCTs are warranted.

Chest. 2012;141:e531S-e575S
What is the risk of TOAT when a novel anticoagulant is used?
Apixaban with Antiplatelet Therapy in ACS
APPRAISE-2

Patients: Patients suffering high risk ACS*
≥ 2 risk factors: age > 65, DM, rec MI, CVD, PAD, HF, EF<40%, CKD

7392 patients

Apixaban 5 mg BID

Placebo

STEMI 40%, NSTEMI 42%
ASA use 97%; P2Y12 use 81%

NEJM 2011;365:699
Efficacy

HR, 0.95 (95% CI, 0.80–1.11); P=0.50

Safety

HR, 2.59 (95% CI, 1.50–4.46); P=0.001

NEJM 2011;365:699
Apixaban with Antiplatelet Therapy in ACS
APPRAISE-2

<table>
<thead>
<tr>
<th>Bleeding</th>
<th>Apixaban/DAPT</th>
<th>Placebo/DAPT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major*</td>
<td>2.4</td>
<td>0.9</td>
</tr>
<tr>
<td>Fatal*</td>
<td>0.3</td>
<td>0</td>
</tr>
<tr>
<td>Intracranial*</td>
<td>0.6</td>
<td>0.2</td>
</tr>
</tbody>
</table>

*p<0.05

NEJM 2011;365:699
Rivaroxaban in Patients with ACS
ATLAS ACS-2 TIMI 51

Patients: Patients suffering ACS

15526 patients

Rivaroxaban 2.5 mg BID

Rivaroxaban 5 mg BID

Placebo

STEMI 50%, NSTEMI 25%
ASA use 99%; P2Y12 use 93%

NEJM 2012;366:9
Efficacy

HR 3.96 (95% CI 2.46-6.38)  
P<0.001

HR 0.84 (95% CI, 0.74–0.96)  
P=0.008

Safety

NEJM 2012;366:9
### Rivaroxaban in Patients with ACS

**ATLAS ACS-2 TIMI 51**

<table>
<thead>
<tr>
<th>Bleeding</th>
<th>Riva 2.5 DAPT</th>
<th>Riva 5 DAPT</th>
<th>Placebo DAPT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major*</td>
<td>1.8</td>
<td>2.4</td>
<td>0.6</td>
</tr>
<tr>
<td>Fatal</td>
<td>0.1</td>
<td>0.4</td>
<td>0.2</td>
</tr>
<tr>
<td>Intracranial*</td>
<td>0.4</td>
<td>0.7</td>
<td>0.2</td>
</tr>
</tbody>
</table>

*p<0.05

NEJM 2012;366:9
Bottom Line: NoACs with TOAT

- Bleeding rates are increased relative to DAPT.
- Absolute bleeding rates however are modest relative to warfarin/TOAT.
- Caution is advised but concept is attractive.
What are the Guideline recommendations regarding TOAT?
Guideline Statements: TOAT

• For AF patients at low to intermediate risk of stroke (CHADS$_2 < 2$) with DES, we suggest DAPT over TOAT (Gr 2C).

• For AF patients at high risk of stroke (CHADS$_2 \geq 2$) with DES, we suggest triple therapy rather than DAPT (Gr 2C).

Chest. 2012;141:e531S-e575S
Guideline Statements: TOAT

• For patients who have an OAC indication, adding warfarin to DAPT is reasonable. (*Class IIb LoE B*)

• Targeting a lower INR (2.0 – 2.5) is reasonable in patients requiring DAPT (*Class IIb; LoE C*).

Circulation. 2012;126:875-910
What are some practical recommendations regarding TOAT?
Practical Points to Ponder

1. Lower INR target (2.0 -2.5)
2. Consider employing BMS
3. Proton pump inhibitor if GI bleed history
4. If low CHADS\textsubscript{2} score (0-1), consider DAPT alone
5. Consider OAC plus clopidogrel
6. Reduce aspirin dose (81 mg/day)
7. Avoid NSAIDs
8. Consider Factor Xa inhibitor instead of warfarin
Question

What antithrombotic cocktail should be used for this patient?

1. Aspirin
2. Clopidogrel (or other P2Y12 antagonist)
3. DAPT
4. OAC
5. TOAT
6. OAC plus clopidogrel
If you offer him TOAT, what will you quote his anxious daughter regarding annual risk of major bleeding?

1. 3%
2. 6%
3. 9%
4. 15%
5. 25%